RIGG GP, MATTHEWS RC, DONOHOE MS, ILLIDGE CM, HODGETTS SJ, WILLIAMSON P, BURNIE JP; Interscience Conference on Antimicrobial Agents and Chemotherapy (42nd : 2002 : San Diego, Calif.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2002 Sep 27-30; 42: abstract no. E-1645.
University of Manchester, Manchester, United Kingdom.
Aurograb is a human-derived single chain variable fragment (scFv) therapeutic antibody which has been developed for the treatment of deep-seated MRSA infections. It is produced as a recombinant protein in E. coli. It has intrinsic antistaphylococcal activity and binds the bacterial cell surface through interaction with a major immunodominant ABC transporter putatively involved in cell wall biosynthesis. In order to study the efficacy of Aurograb against multi-drug resistant Staphylococcus aureus, vancomycin-intermediate derivatives of MRSA (termed VISA) were generated by serial passage through escalating levels of vancomycin. VISA strains were isolated capable of growing on 8 microg mL[-1] vancomycin. MRSA parent strains and VISA strains were subject to MIC assay in the presence of vancomycin. For each MRSA parent strain, addition of Aurograb (100 microg mL[-1]) reduced the MIC of vancomycin by as much as 40 fold. For VISA strains, addition of Aurograb reduced the MIC of vancomycin to levels of 2 microg mL[-1]or less, at which the strain would be considered fully sensitive to vancomycin. These data suggest a synergistic effect for Aurograb and vancomycin, and their use in combination will both increase efficacy and inhibit the appearance of vancomycin-resistant MRSA.
Publication Types:
Keywords:
- Humans
- Microbial Sensitivity Tests
- Staphylococcal Infections
- Staphylococcus aureus
- Vancomycin
- Vancomycin Resistance
Other ID:
UI: 102267427
From Meeting Abstracts